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MaOBJECTIVES The inﬂuence of choice of endpoint on trial size, duration, and interpretation of results was examined in
patients with heart failure who were enrolled in BEST (Beta-blocker Evaluation of Survival Trial).
BACKGROUND The choice of endpoints in heart failure trials has evolved over the past 3 decades.
METHODS In the BEST trial, we used Cox regression analysis to examine the effect of bucindolol on the current standard
composite of cardiovascular death or heart failure hospitalization (CVD/HFH) compared with the original primary mor-
tality endpoint and the expanded composite that included emergency department (ED) visits. We also undertook an
analysis of recurrent events primarily using the Lin, Wei, Ying, and Yang model.
RESULTS Overall, 448 (33%) patients on placebo and 411 (30%) patients on bucindolol died (hazard ratio [HR]: 0.90;
95% conﬁdence interval [CI]: 0.78 to 1.02; p ¼ 0.11). A total of 730 (54%) patients experienced CVD/HFH on placebo and
624 (46%) on bucindolol (HR: 0.80; 95% CI: 0.72 to 0.89; p < 0.001). Adding ED visits increased these numbers to 768
(57%) and 668 (49%), respectively (HR: 0.81; 95% CI: 0.73 to 0.90; p < 0.001). A total of 568 (42%) patients on
placebo experienced HFH compared with 476 (35%) patients on bucindolol (HR: 0.78; 95% CI: 0.69 to 0.89; p < 0.001),
with a total of 1,333 and 1,124 admissions, respectively. With the same statistical assumptions, using the composite
endpoint instead of all-cause mortality would have reduced the trial size by 40% and follow-up duration by 69%.
The rate ratio for recurrent events (CVD/HFH) was 0.83 (95% CI: 0.73 to 0.94; p ¼ 0.003).
CONCLUSIONS Choice of endpoint has major implications for trial size and duration, as well as interpretation of results.
The value of broader composite endpoints and inclusion of recurrent events needs further investigation. (Beta Blocker
Evaluation in Survival Trial [BEST]; NCT00000560) (J Am Coll Cardiol HF 2017;5:591–9) © 2017 by the American
College of Cardiology Foundation.T he choice of endpoints in heart failure (HF)trials has evolved over the past 3 decades.Initially, death from any cause was
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
CV = cardiovascular
CVD = cardiovascular death
ED = emergency department
HF = heart failure
HFH = heart failure
hospitalization
HR = hazard ratio
LVEF = left ventricular
ejection fraction
LWYY = Lin, Wei, Ying, and
Yang
NYHA = New York Heart
Association
WLW = Wei, Lin, and Weissfeld
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592attributable to noncardiovascular causes,
because of the cumulative beneﬁts of effec-
tive treatments on CV mortality (7–9). Simi-
larly, with improving survival and
chronicity of HF, it has been suggested that
analysis of all events, including repeat
events, better reﬂects the overall burden of
the condition than the conventional time-
to-ﬁrst-event analysis (10–14). Recently, clin-
ical practice has evolved, particularly in the
United States, to attempt to manage wors-
ening episodes of HF without formal admis-
sion to hospital. This potentially means that
heart failure hospitalization (HFH) may no
longer reﬂect the true extent of treatment
failure. Consequently, it has been suggested
that these nonhospitalized episodes should
be included in composite outcomes(5,15,16). However, there are few data on the fre-
quency of these and whether they respond to study
treatment in the same way as hospital admission.SEE PAGE 600We used the BEST (Beta-blocker Evaluation of
Survival Trial) to examine the implications of this
evolution in trial endpoints in HF with a reduced
ejection fraction (17,18). BEST is of particular interest
because information of emergency department (ED)
visits and HFHs was collected systematically during
the trial.
METHODS
STUDY DESIGN AND PATIENTS. BEST was a ran-
domized double-blind trial of bucindolol in patients
with HF, funded by the National Heart, Lung, and
Blood Institute and the Department of Veterans Affairs
(17,18). The BEST protocol and results have been pub-
lished. In brief, 2,708 patients with HF with a left
ventricular ejection fraction (LVEF) #35% and New
YorkHeart Association (NYHA) functional class III or IV
symptoms were enrolled in the United States and
Canada from 1995 to 1998, and randomly assigned to
receive bucindolol or placebo. The primary endpoint
was death from any cause. The secondary endpoints
included cardiovascular death (CVD) and HFH. The
cause of death was adjudicated blindly by the central
endpoint committee. The de-identiﬁed public-use
copy of the BEST database provided by the National
Heart, Lung, and Blood Institute, which included all
but 1 participant, was used for the present analysis.
OUTCOMES. HFHs and ED visits for HF were reported
by investigators. Speciﬁcally, the investigator was
asked on the hospitalization or ED visit form tostate whether the visit was due to worsening HF
(“yes” or “no”), for which investigators were
instructed to select “yes” only if the visit was due to
decompensated HF. We deﬁned an isolated ED visit
for HF as one that occurred without a subsequent
HFH within 30 days, and if patients were hospitalized
within 30 days after an ED visit, they were classiﬁed
as having a HFH. The outcomes of interest in this
analysis included: the composite of time to ﬁrst HFH
or CVD; the expanded composite of time to ﬁrst CVD,
HFH, or ED visit for HF; all HFHs (including repeats);
and a composite of all HFHs and CVD (each CVD was
counted as an additional event except when a patient
died during a HF admission).
STATISTICAL ANALYSES. Time-to-ﬁ rs t -event
ana lyses . The baseline characteristics of patients
who had a ﬁrst isolated ED visit for HF, HFH, or CVD,
or none of these events, were compared using anal-
ysis of variance for continuous variables and the chi-
square test for categorical variables. HF duration was
not normally distributed and thus was compared us-
ing the Kruskal-Wallis test.
The association between a ﬁrst nonfatal event (ED
visit for HF or HFH) and subsequent mortality was
examined using time-updated Cox regression anal-
ysis with patients with neither event as the reference
group. The association was adjusted for treatment
assignment and baseline covariates, including age,
sex, race, systolic blood pressure, heart rate, body
mass index, LVEF, NYHA functional class, ischemic
etiology, hypertension, diabetes, myocardial infarc-
tion, atrial ﬁbrillation, previous implantable
cardioverter-deﬁbrillator, and serum creatinine. The
treatment effect on the composite, and on the
expanded composite and its components was exam-
ined using Cox regression analysis.
Assuming all-cause mortality, the composite
endpoint, or the expanded composite as the endpoint,
we examined the time taken to accrue a certain num-
ber of the assumed events. We also examined the
sample size required to detect a 20% reduction in the
assumed endpoint with bucindolol therapy using the
log-rank test, assuming a 2-sided signiﬁcance level of
5%, statistical power of 85%, equal allocation, 3-year
uniform accrual period, a minimum follow-up of 1
year, and a maximum follow-up of 4 years.
RECURRENT EVENTS ANALYSIS. Recurrent events
are commonly analyzed using count data methods
(e.g., negative binomial regression) and time-to-
event data methods (e.g., Andersen-Gill, Wei, Lin,
and Weissfeld [WLW], and Lin, Wei, Ying, and Yang
[LWYY] models), all of which are extensions of Cox
proportional hazards regression (10–13). There is
TABLE 1 Number of Heart Failure Hospitalizations and
Emergency Department Visits for HF by Treatment Group in BEST
Placebo
(n ¼ 1,353)
Bucindolol
(n ¼ 1,354)
Total yrs of follow-up 2,694 2,755
No. of deaths 448 411
No. of CV deaths 388 342
HF hospitalization
Patients with $1 hospitalization 568 476
Patients with $2 hospitalizations 323 246
No. of HF hospitalizations 1,333 1,124
Patients with number of hospitalizations
1 245 230
2 152 97
3 74 61
4 32 27
5 27 24
6 17 13
7 7 9
8 4 4
9 2 4
10 3 3
11 0 1
12 3 1
13 0 1
14 0 1
16 2 0
ED visit for HF
Patients with $1 ED visit 334 281
Patients with $2 ED visits 122 97
No. of ED visits 586 510
Isolated ED visit for HF
Patients with $1 isolated ED visit 161 138
Patients with $2 isolated ED visits 31 25
No. of isolated ED visits 211 176
Values are n.
CV ¼ cardiovascular; ED ¼ emergency department; HF ¼ heart failure.
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593debate about which of these approaches is best to use,
and some considerations about this debate are out-
lined in the Online Appendix. As in the present study,
the event rate and treatment effect were not constant
during follow-up, which violates the assumption of
negative binomial regression; therefore, the LWYY
model was used as the primary method, and the
negative binomial and WLW regressions were used as
sensitivity analyses.
We calculated the HFH rate by treatment group by
dividing the total number of HFHs by the total num-
ber of follow-up years in each group. The cumulative
rates of HFHs over time by treatment group were
plotted using the nonparametric Ghosh and Lin
method, which accounted for the competing risk of
death. Treatment effect on all HFHs and on the
composite of all HFHs and CVD was analyzed pri-
marily using the LWYY model and also using the
negative binomial and WLW regressions. Because of
the inconstant treatment effect on HF hospitalization
over time, sensitivity analyses were performed by
assessing the treatment effects within 6 months and
beyond 6 months since randomization. To account for
the association between HFH and subsequent mor-
tality and the competing risk of mortality on HFHs,
the joint frailty model was used to analyze recurrent
HFHs and time to CVD simultaneously.
A 2-sided p value <0.05 was considered signiﬁcant.
The recurrent event analysis was undertaken using R
version 3.2.3 (R Foundation, Vienna, Austria). All
other analyses were performed using version 14
(Stata, College Station, Texas).
RESULTS
Of the 2,707 patients analyzed, 1,353 were random-
ized to placebo and 1,354 to bucindolol. The median
duration of follow-up was 2.0 years.
DEATHS. Overall, 448 patients (33%) assigned to pla-
cebo and 411 (30%) assigned to bucindolol died with a
hazard ratio (HR) in the bucindolol group of 0.90
(95% conﬁdence interval [CI]: 0.78 to 1.02; p ¼ 0.11).
The number in each treatment group who died from a
CV cause was 388 (29%) and 342 (25%), respectively
(HR: 0.86; 95% CI: 0.75 to 1.00; p ¼ 0.045).
HOSPITAL ADMISSIONS FOR HF. Overall, 568 (42%)
patients assigned to placebo and 476 (35%) patients
assigned to bucindolol had a HFH (HR: 0.78; 95% CI:
0.69 to 0.89; p < 0.001). There was a total of 1,333
admissions in the placebo group and 1,124 in the
bucindolol group (Table 1).
ED VISITS FOR HF. A total of 334 placebo-treated
patients (25%) had an ED visit for HF; there were281 (21%) patients in the bucindolol group (HR: 0.81;
95% CI: 0.69 to 0.95; p ¼ 0.01). Of these, 161 (11.9% of
all patients) and 138 (10.2%) patients, respectively,
were not admitted to hospital (48% and 49% of
patients, respectively, who presented to the ED
were not admitted) (HR: 0.84; 95% CI: 0.67 to 1.06;
p ¼ 0.14). Overall, there were 586 ED visits for HF in
the placebo group and 510 in the bucindolol group. Of
these, 211 (36% of visits) and 176 (35% of visits),
respectively, did not result in a proximate hospital
admission (Table 1).
CHARACTERISTICS OF PATIENTS WITH AN
ADVERSE OUTCOME. The baseline characteristics of
patients who experienced a CVD, HFH, or ED visit for
HF (or none of these) are shown in Table 2. Overall,
patients who died had more characteristics associated
with worse outcome (e.g., older age, lower blood
pressure, estimated glomerular ﬁltration rate, and
TABLE 2 Baseline Characteristics of Patients With First ED Visit for HF, HF Hospitalization, or Neither, or Experiencing CV Death
No Relevant
Event
ED Visit
for HF HF Hospitalization CV Death p Value
n (%) 1,271 (47.0) 199 (7.4) 986 (36.4) 251 (9.3)
Age (yrs) 59.1  12.4 59.6  12.2 61.2  12.3 62.8  11.9 <0.001
Male 982 (77.3) 155 (77.9) 776 (78.7) 201 (80.1) 0.727
Race 0.055
White 911 (71.7) 133 (66.8) 662 (67.1) 189 (75.3)
Black 274 (21.6) 48 (24.1) 256 (26.0) 49 (19.5)
Hispanic 67 (5.3) 11 (5.5) 56 (5.7) 9 (3.6)
Other 19 (1.5) 7 (3.5) 12 (1.2) 4 (1.6)
Blood pressure (mm Hg)
Systolic 119.5  17.9 116.7  18.5 114.5  17.8 115.7  17.9 <0.001
Diastolic 72.3  11.2 71.8  11.8 69.9  10.9 68.8  11.1 <0.001
Heart rate (beats/min) 81.4  13.0 81.2  13.9 82.1  13.4 81.1  12.8 0.566
BMI (kg/m2) 28.3  6.0 29.1  6.4 27.5  5.7 27.1  5.4 <0.001
HF duration* (months) 30 (10–64) 39 (10–72) 41 (16–75) 46 (13–78) <0.001
Left ventricular ejection fraction (%) 24.4  7.0 23.0  7.1 21.7  7.3 21.6  7.1 <0.001
NYHA functional class <0.001
III 1,208 (95.0) 184 (92.5) 869 (88.1) 220 (87.7)
IV 63 (5.0) 15 (7.5) 117 (11.9) 31 (12.4)
Ischemic etiology 672 (52.9) 111 (55.8) 623 (63.2) 181 (72.1) <0.001
Medical history
Myocardial infarction 485 (38.2) 75 (37.7) 452 (45.8) 132 (52.6) <0.001
Angina 618 (48.6) 107 (53.8) 535 (54.3) 140 (55.8) 0.024
CABG 331 (26.0) 60 (30.2) 303 (30.7) 88 (35.1) 0.010
PCI 189 (14.9) 35 (17.6) 161 (16.3) 38 (15.1) 0.672
Hypertension 720 (56.6) 126 (63.3) 598 (60.6) 151 (60.2) 0.129
Diabetes 393 (30.9) 84 (42.2) 380 (38.5) 107 (42.6) <0.001
Atrial ﬁbrillation 263 (20.7) 39 (19.6) 283 (28.7) 68 (27.1) <0.001
Treatment
Randomized treatment 686 (54.0) 97 (48.7) 449 (45.5) 122 (48.6) 0.001
Digitalis 1,141 (89.8) 186 (93.5) 933 (94.6) 239 (95.2) <0.001
Diuretic 1,156 (91.0) 190 (95.5) 946 (95.9) 241 (96.0) <0.001
ACE inhibitor 1,168 (91.9) 183 (92.0) 886 (89.9) 232 (92.4) 0.308
ACE inhibitor or ARB 1,241 (97.6) 195 (98.0) 942 (95.5) 239 (95.2) 0.016
Spironolactone 35 (2.8) 4 (2.0) 43 (4.4) 10 (4.0) 0.121
ICD 36 (2.8) 4 (2.0) 46 (4.7) 4 (1.6) 0.020
Pacemaker 95 (7.5) 19 (9.5) 93 (9.4) 24 (9.6) 0.328
Laboratory measures
Serum creatinine (mg/dl) 1.16  0.36 1.26  0.43 1.32  0.44 1.31  0.40 <0.001
eGFR (ml/min/1.73 m2) 74.2  23.8 69.4  23.8 65.8  25.5 64.4  22.1 <0.001
eGFR <60 ml/min/1.73 m2 347 (28.1) 70 (35.5) 427 (44.4) 118 (48.0) <0.001
Values are n (%) or mean  SD. *HF duration is presented as median with interquartile range.
ACE ¼ angiotensin converting enzyme; ARB ¼ angiotensin II receptor antagonist; BMI ¼ body mass index; CABG ¼ coronary artery bypass grafting; eGFR ¼ estimated
glomerular ﬁltration rate; ICD ¼ implantable cardioverter-deﬁbrillator; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; other abbreviations as
in Table 1.
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594LVEF, ischemic etiology, NYHA functional class IV)
and those who had no events had the least of these
characteristics. Patients with HFHs and ED visits were
in-between these two extremes, although patients
with ED visits appeared less sick, overall, compared
with those who were hospitalized.
ASSOCIATION BETWEEN HF WORSENING AND
SUBSEQUENT MORTALITY. Compared with patientswho did not experience an ED visit (or HFH), those
with an ED visit for HF were subsequently twice as
likely to die during follow-up (HR: 2.05; 95% CI: 1.47
to 2.84; p < 0.001), even after adjustment for other
prognostic variables (HR: 1.90; 1.37 to 2.65; p < 0.001).
In similar analyses, patients hospitalized for wors-
ening HF were 4 times as likely to die (unadjusted
HR: 4.65; 95% CI: 4.02 to 5.37; adjusted HR: 3.72; 95%
CI: 3.20 to 4.33; both p < 0.001).
FIGURE 1 Kaplan-Meier Curves According to Treatment Group
Hazard ratio: 0.80 (0.72-0.89), p <0.001 Placebo
Bucindolol
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
C
V
 d
ea
th
 o
r H
F 
ho
sp
ita
liz
at
io
n
0 .5 1 1.5 2 2.5 3 3.5
Years since randomization
Hazard ratio: 0.81 (0.73-0.90), p <0.001
Placebo
Bucindolol
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
C
V
 d
ea
th
 o
r H
F 
ho
sp
ita
liz
at
io
n 
or
 E
D
 v
is
it
0 .5 1 1.5 2 2.5 3 3.5
Years since randomization
A
B
Kaplan-Meier curves for (A) composite outcome and the (B) expanded composite
outcome according to treatment group. CV ¼ cardiovascular; ED ¼ emergency
department; HF ¼ heart failure.
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595COMPOSITE CLINICAL OUTCOMES. The number of
patients who experienced the composite of ﬁrst HFH
or CVD was 730 (54%) patients and 624 (46%) patients
in the placebo and bucindolol groups, respectively
(HR: 0.80; 95% CI: 0.72 to 0.89; p < 0.001). Adding ED
visits for HF increased the numbers of affected
patients to 768 (57%) and 668 (49%), respectively
(HR: 0.81; 95% CI: 0.73 to 0.90; p < 0.001) (Figure 1).
IMPLICATIONS FOR TRIAL SIZE AND DURATION. The
number of days taken to accrue 500 patients with a
death from any cause was 515; for the composite of
HFH or CVD, this number was 162 days, and for the
expanded composite including ED visits, it was 136
days. There was a substantial decrease in the sample
size using the composite outcomes. For example,
with a power of 85% to detect 20% reduction in the
bucindolol group at a signiﬁcance level of 5%, the
sample size was 2,454 for death from any cause, 1,524
for the composite, and 1,432 for the composite that
included ED visits.
RECURRENT HFHs. There were a total of 1,333 HFHs
in the placebo group and 1,124 HFHs in the bucindolol
group, including 765 (57.4% of all admissions) and
648 (57.7%) repeated admissions, respectively. The
frequencies of HFHs by treatment group are pre-
sented in Table 1. More than 25% of all HF admissions
occurred within 6 months of randomization, and
percentages were 25.2% (n ¼ 336) in the placebo
group and 29.3% (n ¼ 329) in the bucindolol group
(Online Figure 1).
The HFH rates were 49.5 and 40.8 per 100 patient-
years in the placebo and bucindolol groups, respec-
tively. Compared with the placebo group, the
cumulative rate in the bucindolol group was lower
after 6 months, although before 6 months, it was
slightly higher (i.e., the cumulative event curves
crossed over at w6 months). The corresponding
cumulative rate ratio (bucindolol vs. placebo)
appeared to remain constant at approximately
0.83 after 6 months (Figure 2).
Patients with at least 1 HFH were more likely to
have baseline characteristics associated with worse
outcomes (Online Table 1).
For all HFHs, the LWYY regression model gave an
overall HR for bucindolol of 0.82 (95% CI: 0.71 to 0.95;
p ¼ 0.008). A similar estimate was observed from
the WLW model (HR: 0.80; 95% CI: 0.68 to 0.94;
p ¼ 0.005), whereas a smaller and nonsigniﬁcant
effect was obtained from negative binomial and joint
frailty models (both gave a rate ratio of 0.89, with
95% CI: 0.77 to 1.04) (Table 3). However, when sepa-
rate estimations were made for the ﬁrst 6 months
and the remainder of follow-up, the results wereconsistent across different methods. Based on the
LWYY model, the estimate was 0.98 (95% CI: 0.80 to
1.21; p ¼ 0.88) within 6 months and 0.77 (95% CI: 0.65
to 0.91; p ¼ 0.002) after 6 months. Nearly identical
estimates were observed for the composite of all
HFHs and CVD from the corresponding regression
models (Table 3).
DISCUSSION
The purpose of this study was to illustrate the im-
plications of the choice of primary endpoint in clinical
FIGURE 2 Estimated Cumulative Rate and Corresponding Risk Ratios of HFHs
Estimated cumulative rate of heart failure hospitalizations (HFHs) per 100 patients over
time by treatment group and the corresponding risk ratio (bucindolol vs. placebo) for the
cumulative rate of HFHs.
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596trials in HF with a reduced ejection fraction and how
this choice evolved (and continues to evolve) in
recent years. Perhaps the most striking conclusion
was that, had the primary endpoint most commonly
used in recent HF trials been used in BEST, the trial
would have clearly been positive, instead of neutral
or negative as it is historically regarded. This differ-
ence reﬂected 2 things. First, the much larger number
of events in the composite outcome (1,354 composite
events vs. 859 deaths) and the fact that 129 deaths
were noncardiovascular. Although a larger number of
events, per se, did not increase statistical power,TABLE 3 Treatment Effects (Bucindolol vs. Placebo) on All HF hospit
Hospitalizations and Cardiovascular Death Using Different Methods to
Entire Follow-Up
HR/RR (95% CI) p Value
Time to ﬁrst HF hospitalization 0.78 (0.69–0.89) <0.001
All HF hospitalizations
LWYY 0.82 (0.71–0.95) 0.008
WLW 0.80 (0.68–0.94) 0.005
Negative binomial 0.89 (0.77–1.04) 0.137
Joint frailty* 0.89 (0.77–1.04) 0.128
All HF hospitalizations and CV death
LWYY 0.83 (0.73–0.94) 0.003
WLW 0.80 (0.69–0.92) 0.002
Negative binomial 0.89 (0.78–1.01) 0.066
*The corresponding hazard ratio (HR) for CV death in the joint frailty model was 0.93 (95%
0.72 to 1.44; p ¼ 0.91) within 6 months, and 0.86 (95% CI: 0.69 to 1.07; p ¼ 0.17) be
LWYY ¼ Lin, Wei, Ying, and Yang model; RR ¼ rate ratio; WLW ¼ Wei, Lin, and WeissHFHs were events likely to be favorably inﬂuenced by
an effective therapy, and therefore, did increase
power. Conversely, a beta-blocker was unlikely to
decrease the risk of noncardiovascular death, mean-
ing that the 15% of deaths that were not CV effectively
diluted the beneﬁt of bucindolol on the original
primary endpoint (by adding “noise”). As a result,
switching from an all-cause mortality endpoint to the
composite of CVD or HFH would have had a dramatic
impact on sample size in BEST—assuming the same
treatment effect size, power, and signiﬁcance level
(20%, 85%, and 5%, respectively)—the sample size
would have been reduced by nearly 40% (from
n ¼ 2,454 to 1,524), and the time taken to accrue a
requisite number of endpoints (e.g., n ¼ 500) would
have been reduced by an even greater amount (515
to 162 days, a 69% reduction).
Although we found bucindolol reduced the com-
posite of CVD or HFH, a broader composite including
ED visits, and recurrent events, it did not reduce all-
cause mortality, which was demonstrated with 3
other beta-blockers (19). The reason for this remained
uncertain, although the speciﬁc pharmacological
properties of bucindolol, the racial mix of the popu-
lation studied in BEST, and interactions between the
two were implicated (20,21).
Despite a beneﬁt of bucindolol on the composite of
CVD or HFH, an early increase in HFH was observed
among patients treated with bucindolol. HF wors-
ening is a recognized risk early after initiation of beta-
blocker treatment and is believed to be minimized by
starting with a low-dose treatment. This ﬁnding was
also seen in the MERIT-HF (Metoprolol CR/XL Ran-
domized Intervention Trial in Congestive Heart
Failure), although it was apparently not found in thealizations (First and Recurrent) and the Composite of All HF
Analyze Recurrent Events
Within 6 months Beyond 6 months
HR/RR (95% CI) p Value HR/RR (95% CI) p Value
0.88 (0.73–1.06) 0.190 0.72 (0.61–0.84) <0.001
0.98 (0.80–1.21) 0.880 0.77 (0.65–0.91) 0.002
0.99 (0.80–1.23) 0.940 0.74 (0.62–0.89) 0.001
1.00 (0.82–1.24) 0.970 0.80 (0.68–0.95) 0.010
1.02 (0.82–1.27) 0.840 0.80 (0.67–0.95) 0.010
0.97 (0.80–1.18) 0.770 0.78 (0.67–0.90) 0.001
0.98 (0.80–1.19) 0.840 0.75 (0.64–0.88) <0.001
1.00 (0.82–1.21) 0.990 0.80 (0.69–0.93) <0.001
conﬁdence interval [CI]: 0.77 to 1.13; p ¼ 0.47) in the entire follow-up, 1.02 (95% CI:
yond 6 months, respectively.
feld model; other abbreviations as in Table 1.
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597COPERNICUS (Carvedilol Prospective Randomized
Cumulative Survival) trial, which also enrolled pa-
tients with more severe HF, as was done in BEST
(the relevant analysis was not reported for CIBIS-2
(Cardiac Insufﬁciency Bisoprolol Study-2) (22–24).
However, the dose uptitration rate in BEST was more
rapid (weekly) than in the other trials (2 weeks in
COPERNICUS and MERIT-HF; weekly to 5 mg in CIBIS-
2, and then 4 weekly to 10 mg). Another possible
reason could be the potent sympatholytic effect of
bucindolol. A further analysis of BEST showed that a
decrease in plasma norepinephrine levels after 3
months of treatment was associated with higher risk of
death or HFH in the bucindolol group (25).
Because of changing practice, it was suggested that
composite outcomes be further expanded to include
episodes of HF worsening that did not lead to formal
hospital admission (5,15,16,26,27). BEST was unusual
in systematically documenting ED visits. Although
not as numerous as HFHs, ED visits were common.
However, most were associated with a hospital
admission shortly thereafter. Consequently, in a
time-to-ﬁrst-event analysis, isolated ED visits added
relatively few unique events (5%). Nevertheless,
these were enough to shorten the time to accrual of a
target number of events (as used in an event-driven
trial) by approximately 15%. There might be con-
cerns about inclusion of ED visits in the composite
outcome (5,15,16,26,27). First, these events might not
reﬂect worsening of HF in the same way as hospi-
talization, because the events might be less severe or
because patient evaluation during an ED visit might
be less comprehensive than during a hospital
admission. Diagnosis might also be less certain. For
these reasons, ED visits might also be less responsive
to the experimental treatment (especially if mis-
diagnosed). Nevertheless, scrutiny of the character-
istic of patients with ED visits showed they had
features associated with worse outcomes, although
these were less marked than in patients who were
hospitalized or died. In keeping with this, patients
with an ED visit in BEST were subsequently twice as
likely to die compared with those without an ED visit
(or HFH), which conﬁrmed the ﬁndings of another
more recent trial and some epidemiological data
(16,27); patients hospitalized with worsening HF were
4 times as likely to die. The effect of bucindolol on ED
visits was similar to that on CVD and on HFH.
Consequently, including ED visits in the composite
outcome would not only have reduced the study size
(from 1,524 to 1,432 in the previously outlined sce-
nario) and shortened the time to accrual of a target
number of events (e.g., from 162 to 132 days for 500
events), but would also have slightly narrowed the95% CIs around the point estimate for the effect of
bucindolol.
As survival has increased, HF has become a more
chronic condition with recurrent nonfatal hospitali-
zations an increasingly important reﬂection of the
overall burden of the disease on patients and health
care systems alike. This has led to the suggestion
that analysis of all events, including repeated hos-
pital admissions, may provide a better evaluation of
the effect of treatment than time-to-ﬁrst-event
analysis, which has been the conventional approach
used to estimate treatment effect in clinical trials
(5,11–15). A variety of statistical approaches can be
used to do such analyses, and there has been dis-
cussion about which of these is best to use. We
found the two most commonly advocated
approaches (i.e., negative binomial and joint frailty
models) showed somewhat less favorable treatment
effects than the WLW and LWYY models (the prin-
cipal method in this study). This might result from
the violation of 2 important assumptions of negative
binomial regression in BEST, that is, the constant
event rate and the constant treatment effect over
time. This was also the case for the joint frailty
model, which is, in effect, a combination of negative
binomial regression for recurrent HFHs and Cox
regression for time to CVD. The rate of HFHs was
relatively high early after randomization (i.e., over
the ﬁrst 6 months) and lower thereafter. As
mentioned previously, bucindolol treatment led to
an early increase in risk of HF hospitalization fol-
lowed by a later decrease. When estimations were
made separately within 6 months and beyond 6
months, fairly consistent results were observed using
the different modeling approaches.
Interestingly, the proportional reduction in risk
estimated using all of these methods was smaller than
obtained in conventional time-to-ﬁrst-event analysis.
The reason for this observation was uncertain but
might reﬂect the early increase in hospitalization af-
ter initiation of bucindolol before the longer term
reduction in recurrent events with this treatment
became evident. If correct, and whatever the reason,
these ﬁndings highlighted the need to better under-
stand the effect of therapies on recurrent events and
how analyses of these might be used in future clinical
trials.
STUDY LIMITATIONS. First, this was a post hoc
analysis. Second, it was argued that the actions of
bucindolol might be unique among the beta-blockers
tested in large outcome trials, although the beneﬁts
observed in BEST were generally in keeping with
those seen in the other trials (20,28). Third, there was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
choice of primary endpoints has major inﬂuence on
trial size and duration, and on the interpretation of
results. The use of broader composite endpoints
including ED visits for HF worsening may further
reduce trial size and length.
TRANSLATIONAL OUTLOOK: Further studies are
required to determine the values of broader compos-
ite endpoints and inclusion of recurrent events, and to
standardize the approach for the analysis of recurrent
events if included as endpoints.
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598a potential violation of the proportional hazards
assumption for the Cox models in the composite and
the expanded composite outcome analyses, because
of the crossover in the Kaplan-Meier curves, although
the Schoenfeld residuals test was not signiﬁcant for
either (both p value >0.05). Lastly, we only used
investigator-reported HFHs and ED visits in our ana-
lyses; however, a previous analysis showed a similar
treatment effect of bucindolol on ﬁrst hospitaliza-
tions for HF when adjudicated events were used
instead (29).
CONCLUSIONS
The choice of endpoint had major implications for
trial size and duration, as well as interpretation of
results. The use of broader composite endpoints that
included nonhospitalized manifestations of HF
worsening might further reduce sample size and trial
length. However, the role of additional manifesta-
tions of worsening other than ED visits needs further
study. Similarly, the potential role of analysis of
recurrent events as a trial endpoint needs further
investigation. This type of analysis might not give
the same estimate of treatment effect as time-to-
ﬁrst-event analysis, although the level of agreement
might differ for different treatment. However, thisﬁnding did raise the interesting question: which
approach, time-to-ﬁrst-event analysis or analysis of
all (ﬁrst and recurrent) events, gives the more clin-
ically relevant answer?
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